Shattuck Labs (STTK) Stock Price, News & Analysis

Company Overview

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities. Preclinical studies have demonstrated that vaccinated animals produce robust anti‐fentanyl antibody titers and are protected against lethal and sublethal fentanyl challenges. Shattuck Labs is advancing its vaccine candidate through IND‐enabling studies and plans to initiate first‐in‐human trials to evaluate safety, immunogenicity, and its potential to block the psychoactive effects of fentanyl.

Founded in 2017, Shattuck Labs was established to address the growing public health crisis posed by opioid misuse and overdose. The company leverages insights from immunology and vaccinology, collaborating with academic partners and contract manufacturing organizations to streamline development and scale up production. Shattuck Labs serves the U.S. market and is preparing for broader geographic reach as its clinical programs progress.

Shattuck Labs is led by Chief Executive Officer Craig H. Wheeler, who brings extensive experience in biopharmaceutical R&D and commercial strategy. The management team includes experts in vaccine formulation, regulatory affairs, and translational medicine. Through its focused pipeline and innovative platform, Shattuck Labs aims to pioneer a new class of non‐addictive, immunotherapeutic treatments for substance use disorders.

Key Stats

• Today's Range: $6.33 to $6.76
• 50-Day Range: $3.92 to $7.88
• 52-Week Range: $0.71 to $8.33
• Volume: 441,763 shs
• Average Volume: 462,290 shs
• Market Capitalization: $504.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.50
• Consensus Rating: Moderate Buy

Shattuck Labs Stock Analysis - MarketRank™

Shattuck Labs scored higher than 70% of companies evaluated by MarketBeat, and ranked 210th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Shattuck Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Shattuck Labs has a consensus price target of $12.50, representing about 87.1% upside from its current price of $6.68.

Amount of Analyst Coverage

Shattuck Labs has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Shattuck Labs are expected to decrease in the coming year, from ($0.48) to ($0.49) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Shattuck Labs is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shattuck Labs is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Shattuck Labs has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.01% of the float of Shattuck Labs has been sold short.

Short Interest Ratio / Days to Cover

Shattuck Labs has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shattuck Labs has recently decreased by 8.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Shattuck Labs does not currently pay a dividend.

Dividend Growth

Shattuck Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.64

News Sentiment

Shattuck Labs has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Shattuck Labs this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for STTK on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

2 people have added Shattuck Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shattuck Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.79% of the stock of Shattuck Labs is held by insiders.

Percentage Held by Institutions

58.74% of the stock of Shattuck Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STTK Stock Analysis - Frequently Asked Questions

How have STTK shares performed this year?

Shattuck Labs' stock was trading at $3.65 at the beginning of 2026. Since then, STTK stock has increased by 83.0% and is now trading at $6.68.

How were Shattuck Labs' earnings last quarter?

Shattuck Labs, Inc. (NASDAQ:STTK) released its quarterly earnings results on Thursday, March, 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The company earned ($1) million during the quarter, compared to analyst estimates of $0.17 million.

When did Shattuck Labs IPO?

Shattuck Labs (STTK) raised $178 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 11,882,352 shares at $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI acted as the underwriters for the IPO and Needham & Co. was co-manager.

Who are Shattuck Labs' major shareholders?

Shattuck Labs' top institutional shareholders include Bank of New York Mellon Corp (0.12%), Hillsdale Investment Management Inc. (0.09%) and Hsbc Holdings PLC (0.06%). Insiders that own company stock include Redmile Group, Llc, Orbimed Advisors Llc, Mona Ashiya, Tyler Brous, Andrew R Neill, Stephen Stout and Taylor Schreiber.
View institutional ownership trends.

How do I buy shares of Shattuck Labs?

Shares of STTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Shattuck Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shattuck Labs investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 3/05/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:STTK
• CIK: 1680367
• Web: www.shattucklabs.com
• Phone: 512-900-4690
• Fax: N/A
• Employees: 100
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Shattuck Labs: $12.50
• High Price Target: $25.00
• Low Price Target: $2.00
• Potential Upside/Downside: +87.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.81 million
• Net Margins: N/A
• Pretax Margin: -4,880.90%
• Return on Equity: -65.03%
• Return on Assets: -58.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.69
• Quick Ratio: 11.70

Sales & Book Value

• Annual Sales: $1 million
• Price / Sales: 504.87
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: 5.14

Miscellaneous

• Outstanding Shares: 75,580,000
• Free Float: 68,938,000
• Market Cap: $504.87 million
• Optionable: Optionable
• Beta: 1.18